🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Siemens Healthineers stock downgraded as Chinese market pressure mounts - UBS

EditorEmilio Ghigini
Published 2024-09-26, 03:28 a/m
SHLG
-


On Thursday, Siemens Healthineers AG (SHL:GR) (OTC: SEMHF) experienced a change in stock rating as UBS downgraded the company from Buy to Neutral. Alongside this adjustment, the price target was also reduced to EUR51.00 from the previous target of EUR56.00.

The downgrade was prompted by the anticipated underperformance in the significant Chinese market, which is expected to hinder growth in the short term.

UBS's assessment of Siemens Healthineers underscores the company's standing as a market leader in the Imaging sector, renowned for delivering high-quality products. However, the firm projects that growth in China will fall short of expectations, even with a potential stimulus in 2025. This outlook positions UBS's forecasts for Siemens Healthineers 5% below the consensus for the next year.

Looking at the mid-term, UBS anticipates emerging Chinese competitors to capture market share, which is likely to reduce the growth rate for Western Imaging market players from 5% to 3%. This shift is expected to moderate the growth trajectory for Siemens Healthineers.

The firm's analysis, detailed in their recently published deep dive Q-Series, suggests that the subdued growth will prevent Siemens Healthineers from achieving above-sector growth, which in turn has led to the revised Neutral rating.

Concluding their statement, UBS acknowledged the intrinsic quality and strong market positions of Siemens Healthineers. Nevertheless, the absence of expected above-sector growth has led to the conclusion that the shares are unlikely to experience a re-rating compared to the sector. As a result, UBS has opted to lower their rating to Neutral.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.